About this trial
Early diabetic kidney disease (DKD) occurs in 50-70% of youth with type 2 diabetes (T2D) and confers high lifetime risk of dialysis and premature death. Youth-onset T2D typically manifests during or shortly after puberty in adolescents with obesity. Epidemiological data implicate puberty as an accelerator of kidney disease in youth with obesity and diabetes and the investigators posit that the link between puberty and T2D-onset may explain the high burden of DKD in youth-onset T2D. A better understanding of the impact of puberty on kidney health is needed to promote preservation of native kidney function, especially in youth with T2D.
Eligibility criteria
Qualifiers
HbA1c ≥6.0% for untreated high-risk group
BMI ≥ 85th %ile for high-risk group
Normal HbA1c ≤5.6% for control group
Type 1 diabetes (T1D) Antibody negative
Disqualifiers
History of Chronic kidney disease (CKD) or acute kidney injury (AKI)
Metabolic disorder prohibiting safe fasting
Iodine or penicillin allergy
Pregnancy
Trial design
Treatments tested in this trial
- Aminohippurate Sodium Inj 20%
- Iohexol Inj 300 MG/ML
- Dextran 40
Treatment groups
Sponsors and collaborators
Petter Bjornstad
Lead sponsor
Seattle Children's Hospital
Sponsor institution
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Seattle Children's Hospital
Collaborator
University of Colorado, Denver
Collaborator